Trials / Completed
CompletedNCT04246749
Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers
A Phase 1, Open-label, Two-cohort, Single Dose Study to Assess the Mass Balance, Route of Elimination, and Metabolic Profile of [14C] Labeled CRN00808 and Absolute Bioavailability of CRN00808 in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Crinetics Pharmaceuticals Inc. · Industry
- Sex
- Male
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A phase 1 healthy volunteer study to assess the mass balance, elimination, and metabolic profile of CRN00808. The study will be conducted in 2 parts: Part A, to characterize the absorption, distribution, metabolism, excretion, and mass balance of orally administered radio-labeled CRN00808; Part B, to determine the absolute bioavailability of CRN00808 administered using CRN00808 and radio-labeled CRN00808 as intravenous and oral forms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-CRN00808 | Investigational drug |
| DRUG | CRN00808 | Investigational drug |
Timeline
- Start date
- 2019-09-17
- Primary completion
- 2019-10-25
- Completion
- 2019-10-25
- First posted
- 2020-01-29
- Last updated
- 2020-01-29
Locations
1 site across 1 country: Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04246749. Inclusion in this directory is not an endorsement.